Vascular oxidative stress, nitric oxide and atherosclerosis

Zhang, 2007, Mitochondrial reactive oxygen species-mediated signaling in endothelial cells, Am J Physiol Heart Circ Physiol, 292, H2023, 10.1152/ajpheart.01283.2006 Stocker, 2004, Role of oxidative modifications in atherosclerosis, Physiol Rev, 84, 1381, 10.1152/physrev.00047.2003 Harrison, 2003, Role of oxidative stress in atherosclerosis, Am J Cardiol, 91, 7A, 10.1016/S0002-9149(02)03144-2 Forstermann, 2008, Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies, Nat Clin Pract Cardiovasc Med, 5, 338, 10.1038/ncpcardio1211 Li, 2013, Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease, Curr Opin Pharmacol, 13, 161, 10.1016/j.coph.2013.01.006 Borradaile, 2006, Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death, J Lipid Res, 47, 2726, 10.1194/jlr.M600299-JLR200 Maxfield, 2005, Role of cholesterol and lipid organization in disease, Nature, 438, 612, 10.1038/nature04399 Zhou, 2005, Activation of the unfolded protein response occurs at all stages of atherosclerotic lesion development in apolipoprotein E-deficient mice, Circulation, 111, 1814, 10.1161/01.CIR.0000160864.31351.C1 Gargalovic, 2006, The unfolded protein response is an important regulator of inflammatory genes in endothelial cells, Arterioscler Thromb Vasc Biol, 26, 2490, 10.1161/01.ATV.0000242903.41158.a1 Galan, 2014, Mechanism of endoplasmic reticulum stress-induced vascular endothelial dysfunction, Biochim Biophys Acta, 1843, 1063, 10.1016/j.bbamcr.2014.02.009 Gorlach, 2006, The endoplasmic reticulum: folding, calcium homeostasis, signaling, and redox control, Antioxid Redox Signal, 8, 1391, 10.1089/ars.2006.8.1391 Tu, 2004, Oxidative protein folding in eukaryotes: mechanisms and consequences, J Cell Biol, 164, 341, 10.1083/jcb.200311055 Devries-Seimon, 2005, Cholesterol-induced macrophage apoptosis requires ER stress pathways and engagement of the type A scavenger receptor, J Cell Biol, 171, 61, 10.1083/jcb.200502078 Feng, 2003, The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages, Nat Cell Biol, 5, 781, 10.1038/ncb1035 McCullough, 2001, Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state, Mol Cell Biol, 21, 1249, 10.1128/MCB.21.4.1249-1259.2001 Sovolyova, 2014, Stressed to death - mechanisms of ER stress-induced cell death, Biol Chem, 395, 1, 10.1515/hsz-2013-0174 Gorman, 2012, Stress management at the ER: regulators of ER stress-induced apoptosis, Pharmacol Ther, 134, 306, 10.1016/j.pharmthera.2012.02.003 Zhou, 2013, The UPR in atherosclerosis, Semin Immunopathol, 35, 321, 10.1007/s00281-013-0372-x Ozcan, 2012, Role of endoplasmic reticulum stress in metabolic disease and other disorders, Annu Rev Med, 63, 317, 10.1146/annurev-med-043010-144749 Ozcan, 2006, Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes, Science, 313, 1137, 10.1126/science.1128294 Thorp, 2009, Mechanisms and consequences of efferocytosis in advanced atherosclerosis, J Leukoc Biol, 86, 1089, 10.1189/jlb.0209115 Tsukano, 2010, The endoplasmic reticulum stress-C/EBP homologous protein pathway-mediated apoptosis in macrophages contributes to the instability of atherosclerotic plaques, Arterioscler Thromb Vasc Biol, 30, 1925, 10.1161/ATVBAHA.110.206094 Thorp, 2009, Reduced apoptosis and plaque necrosis in advanced atherosclerotic lesions of Apoe−/− and Ldlr−/− mice lacking CHOP, Cell Metab, 9, 474, 10.1016/j.cmet.2009.03.003 Breton-Romero, 2012, Critical role of hydrogen peroxide signaling in the sequential activation of p38 MAPK and eNOS in laminar shear stress, Free Radic Biol Med, 52, 1093, 10.1016/j.freeradbiomed.2011.12.026 Park, 2011, Peroxiredoxin 2 deficiency exacerbates atherosclerosis in apolipoprotein E-deficient mice, Circ Res, 109, 739, 10.1161/CIRCRESAHA.111.245530 Aono, 2012, Deletion of the angiotensin II type 1a receptor prevents atherosclerotic plaque rupture in apolipoprotein E−/− mice, Arterioscler Thromb Vasc Biol, 32, 1453, 10.1161/ATVBAHA.112.249516 Han, 2010, Angiotensin II induces C-reactive protein expression through ERK1/2 and JNK signaling in human aortic endothelial cells, Atherosclerosis, 212, 206, 10.1016/j.atherosclerosis.2010.05.020 Su, 2009, The interleukin-1 receptor-associated kinase M selectively inhibits the alternative, instead of the classical NFkappaB pathway, J Innate Immun, 1, 164 Landmesser, 2007, Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease, Arterioscler Thromb Vasc Biol, 27, 943, 10.1161/01.ATV.0000258415.32883.bf Drummond, 2011, Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets, Nat Rev Drug Discov, 10, 453, 10.1038/nrd3403 Bedard, 2007, The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology, Physiol Rev, 87, 245, 10.1152/physrev.00044.2005 Brandes, 2005, Vascular NADPH oxidases: molecular mechanisms of activation, Cardiovasc Res, 65, 16, 10.1016/j.cardiores.2004.08.007 Lassegue, 2001, Novel gp91(phox) homologues in vascular smooth muscle cells : nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways, Circ Res, 88, 888, 10.1161/hh0901.090299 Ellmark, 2005, The contribution of Nox4 to NADPH oxidase activity in mouse vascular smooth muscle, Cardiovasc Res, 65, 495, 10.1016/j.cardiores.2004.10.026 Gorlach, 2000, A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall, Circ Res, 87, 26, 10.1161/01.RES.87.1.26 Ago, 2004, Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase, Circulation, 109, 227, 10.1161/01.CIR.0000105680.92873.70 Xu, 2008, Differential roles of PKCalpha and PKCepsilon in controlling the gene expression of Nox4 in human endothelial cells, Free Radic Biol Med, 44, 1656, 10.1016/j.freeradbiomed.2008.01.023 Guzik, 2006, Coronary artery superoxide production and nox isoform expression in human coronary artery disease, Arterioscler Thromb Vasc Biol, 26, 333, 10.1161/01.ATV.0000196651.64776.51 Judkins, 2010, Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE−/− mice, Am J Physiol Heart Circ Physiol, 298, H24, 10.1152/ajpheart.00799.2009 Kirk, 2000, Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice, Arterioscler Thromb Vasc Biol, 20, 1529, 10.1161/01.ATV.20.6.1529 Hsich, 2000, Vascular effects following homozygous disruption of p47(phox) : an essential component of NADPH oxidase, Circulation, 101, 1234, 10.1161/01.CIR.101.11.1234 Barry-Lane, 2001, p47phox is required for atherosclerotic lesion progression in ApoE(−/−) mice, J Clin Invest, 108, 1513, 10.1172/JCI200111927 Douglas, 2012, Endothelial-specific Nox2 overexpression increases vascular superoxide and macrophage recruitment in ApoE(-)/(-) mice, Cardiovasc Res, 94, 20, 10.1093/cvr/cvs026 Sorescu, 2002, Superoxide production and expression of nox family proteins in human atherosclerosis, Circulation, 105, 1429, 10.1161/01.CIR.0000012917.74432.66 Haendeler, 2012, Endothelial NADPH oxidase 2: when does it matter in atherosclerosis?, Cardiovasc Res, 94, 1, 10.1093/cvr/cvs106 White, 1996, Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits, Proc Natl Acad Sci U S A, 93, 8745, 10.1073/pnas.93.16.8745 Ohara, 1993, Hypercholesterolemia increases endothelial superoxide anion production, J Clin Invest, 91, 2546, 10.1172/JCI116491 Patetsios, 2001, Identification of uric acid and xanthine oxidase in atherosclerotic plaque, Am J Cardiol, 88, 188, 10.1016/S0002-9149(01)01621-6 Guthikonda, 2003, Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers, Circulation, 107, 416, 10.1161/01.CIR.0000046448.26751.58 Schroder, 2006, Xanthine oxidase inhibitor tungsten prevents the development of atherosclerosis in ApoE knockout mice fed a Western-type diet, Free Radic Biol Med, 41, 1353, 10.1016/j.freeradbiomed.2006.03.026 Leopold, 2009, Oxidative risk for atherothrombotic cardiovascular disease, Free Radic Biol Med, 47, 1673, 10.1016/j.freeradbiomed.2009.09.009 Sugamura, 2011, Reactive oxygen species in cardiovascular disease, Free Radic Biol Med, 51, 978, 10.1016/j.freeradbiomed.2011.05.004 Li, 1995, Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase, Nat Genet, 11, 376, 10.1038/ng1295-376 Nojiri, 2006, Oxidative stress causes heart failure with impaired mitochondrial respiration, J Biol Chem, 281, 33789, 10.1074/jbc.M602118200 Chouchani, 2013, Cardioprotection by S-nitrosation of a cysteine switch on mitochondrial complex I, Nat Med, 19, 753, 10.1038/nm.3212 Mercer, 2012, The mitochondria-targeted antioxidant MitoQ decreases features of the metabolic syndrome in ATM+/−/ApoE−/− mice, Free Radic Biol Med, 52, 841, 10.1016/j.freeradbiomed.2011.11.026 Wang, 2010, CYFRA21-1 can predict the sensitivity to chemoradiotherapy of non-small-cell lung carcinoma, Biomarkers, 15, 594, 10.3109/1354750X.2010.504308 Jin, 2014, Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes, Biochim Biophys Acta, 1842, 1282, 10.1016/j.bbadis.2013.09.007 Yu, 2013, Mitochondrial DNA damage can promote atherosclerosis independently of reactive oxygen species through effects on smooth muscle cells and monocytes and correlates with higher-risk plaques in humans, Circulation, 128, 702, 10.1161/CIRCULATIONAHA.113.002271 Li, 2000, Nitric oxide in the pathogenesis of vascular disease, J Pathol, 190, 244, 10.1002/(SICI)1096-9896(200002)190:3<244::AID-PATH575>3.0.CO;2-8 Li, 2009, Prevention of atherosclerosis by interference with the vascular nitric oxide system, Curr Pharm Des, 15, 3133, 10.2174/138161209789058002 Forstermann, 2012, Nitric oxide synthases: regulation and function, Eur Heart J, 33, 10.1093/eurheartj/ehr304 Li, 2013, Oxidative stress in vascular disease and its pharmacological prevention, Trends Pharmacol Sci, 34, 313, 10.1016/j.tips.2013.03.007 Forstermann, 2006, Endothelial nitric oxide synthase in vascular disease: from marvel to menace, Circulation, 113, 1708, 10.1161/CIRCULATIONAHA.105.602532 Alp, 2004, Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice, Arterioscler Thromb Vasc Biol, 24, 445, 10.1161/01.ATV.0000115637.48689.77 Wohlfart, 2008, Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling, J Pharmacol Exp Ther, 325, 370, 10.1124/jpet.107.128009 Xia, 2010, Resveratrol reverses endothelial nitric-oxide synthase uncoupling in apolipoprotein E knockout mice, J Pharmacol Exp Ther, 335, 149, 10.1124/jpet.110.168724 Stroes, 1997, Tetrahydrobiopterin restores endothelial function in hypercholesterolemia, J Clin Invest, 99, 41, 10.1172/JCI119131 Heitzer, 2000, Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with type II diabetes mellitus, Diabetologia, 43, 1435, 10.1007/s001250051551 Ueda, 2000, Tetrahydrobiopterin restores endothelial function in long-term smokers, J Am Coll Cardiol, 35, 71, 10.1016/S0735-1097(99)00523-9 Drouin, 2007, Endothelial nitric oxide synthase activation leads to dilatory H2O2 production in mouse cerebral arteries, Cardiovasc Res, 73, 73, 10.1016/j.cardiores.2006.10.005 Drouin, 2009, Flow-induced dilation is mediated by Akt-dependent activation of endothelial nitric oxide synthase-derived hydrogen peroxide in mouse cerebral arteries, Stroke, 40, 1827, 10.1161/STROKEAHA.108.536805 Yokoyama, 2007, Endothelial nitric oxide synthase uncoupling: is it a physiological mechanism of endothelium-dependent relaxation in cerebral artery?, Cardiovasc Res, 73, 8, 10.1016/j.cardiores.2006.11.009 Fukai, 2011, Superoxide dismutases: role in redox signaling, vascular function, and diseases, Antioxid Redox Signal, 15, 1583, 10.1089/ars.2011.3999 Tribble, 1997, Fatty streak formation in fat-fed mice expressing human copper-zinc superoxide dismutase, Arterioscler Thromb Vasc Biol, 17, 1734, 10.1161/01.ATV.17.9.1734 Nelson, 1994, The toxicity of high-dose superoxide dismutase suggests that superoxide can both initiate and terminate lipid peroxidation in the reperfused heart, Free Radic Biol Med, 16, 195, 10.1016/0891-5849(94)90143-0 Yang, 2004, Retardation of atherosclerosis by overexpression of catalase or both Cu/Zn-superoxide dismutase and catalase in mice lacking apolipoprotein E, Circ Res, 95, 1075, 10.1161/01.RES.0000149564.49410.0d Ballinger, 2002, Mitochondrial integrity and function in atherogenesis, Circulation, 106, 544, 10.1161/01.CIR.0000023921.93743.89 Sentman, 2001, Extracellular superoxide dismutase deficiency and atherosclerosis in mice, Arterioscler Thromb Vasc Biol, 21, 1477, 10.1161/hq0901.094248 Zhang, 2005, Vascular hypertrophy in angiotensin II-induced hypertension is mediated by vascular smooth muscle cell-derived H2O2, Hypertension, 46, 732, 10.1161/01.HYP.0000182660.74266.6d Yang, 2009, Overexpression of antioxidant enzymes in ApoE-deficient mice suppresses benzo(a)pyrene-accelerated atherosclerosis, Atherosclerosis, 207, 51, 10.1016/j.atherosclerosis.2009.03.052 Asmis, 2003, Oxidized LDL promotes peroxide-mediated mitochondrial dysfunction and cell death in human macrophages: a caspase-3-independent pathway, Circ Res, 92, e20, 10.1161/01.RES.0000051886.43510.90 Tribble, 1999, Ionizing radiation accelerates aortic lesion formation in fat-fed mice via SOD-inhibitable processes, Arterioscler Thromb Vasc Biol, 19, 1387, 10.1161/01.ATV.19.6.1387 Lubos, 2011, Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities, Antioxid Redox Signal, 15, 1957, 10.1089/ars.2010.3586 Blankenberg, 2003, Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease, N Engl J Med, 349, 1605, 10.1056/NEJMoa030535 Cheng, 2013, Impact of glutathione peroxidase-1 deficiency on macrophage foam cell formation and proliferation: implications for atherogenesis, PLoS One, 8, e72063, 10.1371/journal.pone.0072063 de Haan, 2006, Lack of the antioxidant glutathione peroxidase-1 does not increase atherosclerosis in C57BL/J6 mice fed a high-fat diet, J Lipid Res, 47, 1157, 10.1194/jlr.M500377-JLR200 Torzewski, 2007, Deficiency of glutathione peroxidase-1 accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice, Arterioscler Thromb Vasc Biol, 27, 850, 10.1161/01.ATV.0000258809.47285.07 Lewis, 2007, Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice, Circulation, 115, 2178, 10.1161/CIRCULATIONAHA.106.664250 Chew, 2009, Site-specific antiatherogenic effect of the antioxidant ebselen in the diabetic apolipoprotein E-deficient mouse, Arterioscler Thromb Vasc Biol, 29, 823, 10.1161/ATVBAHA.109.186619 Imai, 2003, Biological significance of phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) in mammalian cells, Free Radic Biol Med, 34, 145, 10.1016/S0891-5849(02)01197-8 Guo, 2008, Suppression of atherogenesis by overexpression of glutathione peroxidase-4 in apolipoprotein E-deficient mice, Free Radic Biol Med, 44, 343, 10.1016/j.freeradbiomed.2007.09.009 Draganov, 2005, Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities, J Lipid Res, 46, 1239, 10.1194/jlr.M400511-JLR200 Mackness, 1993, Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase, Atherosclerosis, 104, 129, 10.1016/0021-9150(93)90183-U Shih, 1998, Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis, Nature, 394, 284, 10.1038/28406 Tward, 2002, Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice, Circulation, 106, 484, 10.1161/01.CIR.0000023623.87083.4F Huang, 2013, Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex, J Clin Invest, 123, 3815, 10.1172/JCI67478 Aharoni, 2013, Paraoxonase 1 (PON1) reduces macrophage inflammatory responses, Atherosclerosis, 228, 353, 10.1016/j.atherosclerosis.2013.03.005 Mackness, 2013, Targeting paraoxonase-1 in atherosclerosis, Expert Opin Ther Targets, 17, 829, 10.1517/14728222.2013.790367 Aviram, 2013, Paraoxonase 1 activities, regulation, and interactions with atherosclerotic lesion, Curr Opin Lipidol, 24, 339, 10.1097/MOL.0b013e32835ffcfd Costa, 2005, Paraoxonase (PON1): from toxicology to cardiovascular medicine, Acta Biomed, 2, 50 Ng, 2001, Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein, J Biol Chem, 276, 44444, 10.1074/jbc.M105660200 Ng, 2006, Adenovirus mediated expression of human paraoxonase 2 protects against the development of atherosclerosis in apolipoprotein E-deficient mice, Mol Genet Metab, 89, 368, 10.1016/j.ymgme.2006.07.004 Ng, 2006, Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2, J Biol Chem, 281, 29491, 10.1074/jbc.M605379200 Witte, 2012, Protectors or traitors: the roles of PON2 and PON3 in atherosclerosis and Cancer, J Lipids, 2012, 342806 Horke, 2007, Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stress-induced caspase activation, Circulation, 115, 2055, 10.1161/CIRCULATIONAHA.106.681700 Hagmann, 2014, Breaking the chain at the membrane: paraoxonase 2 counteracts lipid peroxidation at the plasma membrane, FASEB J, 28, 1769, 10.1096/fj.13-240309 Fortunato, 2008, Decreased paraoxonase-2 expression in human carotids during the progression of atherosclerosis, Arterioscler Thromb Vasc Biol, 28, 594, 10.1161/ATVBAHA.107.154658 Draganov, 2000, Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation, J Biol Chem, 275, 33435, 10.1074/jbc.M004543200 Schweikert, 2012, PON3 is upregulated in cancer tissues and protects against mitochondrial superoxide-mediated cell death, Cell Death Differ, 19, 1549, 10.1038/cdd.2012.35 Shih, 2007, Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice, Circ Res, 100, 1200, 10.1161/01.RES.0000264499.48737.69 Marsillach, 2011, Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques, Eur J Clin Invest, 41, 308, 10.1111/j.1365-2362.2010.02411.x Reny, 2012, Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis, J Thromb Haemost, 10, 1242, 10.1111/j.1538-7836.2012.04756.x Fefer, 2011, The genetic basis of platelet responsiveness to clopidogrel. A critical review of the literature, Thromb Haemost, 106, 203, 10.1160/TH11-04-0228 Riedmaier, 2011, Paraoxonase (PON1 and PON3) polymorphisms: impact on liver expression and atorvastatin-lactone hydrolysis, Front Pharmacol, 2, 41, 10.3389/fphar.2011.00041 Griffin, 2012, Expression of PPARgamma and paraoxonase 2 correlated with Pseudomonas aeruginosa infection in cystic fibrosis, PLoS One, 7, 10.1371/journal.pone.0042241 Schweikert, 2012, Paraoxonases-2 and -3 are important defense enzymes against Pseudomonas aeruginosa virulence factors due to their anti-oxidative and anti-inflammatory properties, J Lipids, 2012, 352857 Simanski, 2012, Paraoxonase 2 acts as a quorum sensing-quenching factor in human keratinocytes, J Invest Dermatol, 132, 2296, 10.1038/jid.2012.128 Teiber, 2008, Dominant role of paraoxonases in inactivation of the Pseudomonas aeruginosa quorum-sensing signal N-(3-oxododecanoyl)-L-homoserine lactone, Infect Immun, 76, 2512, 10.1128/IAI.01606-07 Liu, 2008, Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice, Cardiovasc Res, 77, 19 Melikian, 2009, Neuronal nitric oxide synthase and human vascular regulation, Trends Cardiovasc Med, 19, 256, 10.1016/j.tcm.2010.02.007 Schwarz, 1999, Potential functional significance of brain-type and muscle-type nitric oxide synthase I expressed in adventitia and media of rat aorta, Arterioscler Thromb Vasc Biol, 19, 2584, 10.1161/01.ATV.19.11.2584 Tsutsui, 2004, Neuronal nitric oxide synthase as a novel anti-atherogenic factor, J Atheroscler Thromb, 11, 41, 10.5551/jat.11.41 Seddon, 2008, Neuronal nitric oxide synthase regulates basal microvascular tone in humans in vivo, Circulation, 117, 1991, 10.1161/CIRCULATIONAHA.107.744540 Seddon, 2009, Effects of neuronal nitric oxide synthase on human coronary artery diameter and blood flow in vivo, Circulation, 119, 2656, 10.1161/CIRCULATIONAHA.108.822205 Kellogg, 2008, Neuronal nitric oxide synthase control mechanisms in the cutaneous vasculature of humans in vivo, J Physiol, 586, 847, 10.1113/jphysiol.2007.144642 Kuhlencordt, 2006, Atheroprotective effects of neuronal nitric oxide synthase in apolipoprotein e knockout mice, Arterioscler Thromb Vasc Biol, 26, 1539, 10.1161/01.ATV.0000223143.88128.19 Schodel, 2009, Expression of neuronal nitric oxide synthase splice variants in atherosclerotic plaques of apoE knockout mice, Atherosclerosis, 206, 383, 10.1016/j.atherosclerosis.2009.02.033 Morishita, 2002, Vasculoprotective roles of neuronal nitric oxide synthase, FASEB J, 16, 1994, 10.1096/fj.02-0155fje Pautz, 2010, Regulation of the expression of inducible nitric oxide synthase, Nitric Oxide, 23, 75, 10.1016/j.niox.2010.04.007 Gunnett, 2005, Mechanisms of inducible nitric oxide synthase-mediated vascular dysfunction, Arterioscler Thromb Vasc Biol, 25, 1617, 10.1161/01.ATV.0000172626.00296.ba Chen, 2010, NO contributes to abnormal vascular calcium regulation and reactivity induced by peritonitis-associated septic shock in rats, Shock, 33, 473, 10.1097/SHK.0b013e3181bea334 Shelkovnikov, 2004, Peroxynitrite but not nitric oxide donors destroys epinephrine: HPLC measurement and rat aorta contractility, Life Sci, 75, 2765, 10.1016/j.lfs.2004.04.044 Kessler, 1997, Inhibition of inducible nitric oxide synthase restores endothelium-dependent relaxations in proinflammatory mediator-induced blood vessels, Arterioscler Thromb Vasc Biol, 17, 1746, 10.1161/01.ATV.17.9.1746 Virdis, 2005, Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: role of inducible nitric-oxide synthase and oxidative stress, J Pharmacol Exp Ther, 312, 945, 10.1124/jpet.104.077644 Eguchi, 2002, Inhibitory effect of recombinant iNOS gene expression on vasomotor function of canine basilar artery, Am J Physiol Heart Circ Physiol, 283, H2560, 10.1152/ajpheart.00415.2002 Xia, 1997, Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages, Proc Natl Acad Sci U S A, 94, 6954, 10.1073/pnas.94.13.6954 Marfella, 2004, Absence of inducible nitric oxide synthase reduces myocardial damage during ischemia reperfusion in streptozotocin-induced hyperglycemic mice, Diabetes, 53, 454, 10.2337/diabetes.53.2.454 Depre, 1999, Expression of inducible nitric oxide synthase in human coronary atherosclerotic plaque, Cardiovasc Res, 41, 465, 10.1016/S0008-6363(98)00304-6 Pacher, 2007, Nitric oxide and peroxynitrite in health and disease, Physiol Rev, 87, 315, 10.1152/physrev.00029.2006 Liaudet, 2013, Role of peroxynitrite in the cardiovascular dysfunction of septic shock, Curr Vasc Pharmacol, 11, 196 Wilcox, 1997, Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels, Arterioscler Thromb Vasc Biol, 17, 2479, 10.1161/01.ATV.17.11.2479 Baker, 1999, Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages, Arterioscler Thromb Vasc Biol, 19, 646, 10.1161/01.ATV.19.3.646 Kuhlencordt, 2001, Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice, Circulation, 103, 3099, 10.1161/01.CIR.103.25.3099 Li, 2014, Pharmacological prevention of eNOS Uncoupling, Curr Pharm Des, 20, 3595, 10.2174/13816128113196660749 Kuhlencordt, 2001, Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice, Circulation, 104, 448, 10.1161/hc2901.091399 Chen, 2001, Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitric oxide synthase double knockout mice, Circulation, 104, 2391, 10.1161/hc4501.099729 Ozaki, 2002, Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice, J Clin Invest, 110, 331, 10.1172/JCI0215215 Takaya, 2007, A specific role for eNOS-derived reactive oxygen species in atherosclerosis progression, Arterioscler Thromb Vasc Biol, 27, 1632, 10.1161/ATVBAHA.107.142182 Ponnuswamy, 2012, eNOS protects from atherosclerosis despite relevant superoxide production by the enzyme in apoE mice, PLoS One, 7, e30193, 10.1371/journal.pone.0030193 Kauser, 2000, Role of endogenous nitric oxide in progression of atherosclerosis in apolipoprotein E-deficient mice, Am J Physiol Heart Circ Physiol, 278, H1679, 10.1152/ajpheart.2000.278.5.H1679 Vendrov, 2007, Atherosclerosis is attenuated by limiting superoxide generation in both macrophages and vessel wall cells, Arterioscler Thromb Vasc Biol, 27, 2714, 10.1161/ATVBAHA.107.152629 Borissoff, 2010, Early atherosclerosis exhibits an enhanced procoagulant state, Circulation, 122, 821, 10.1161/CIRCULATIONAHA.109.907121 Rowley, 2011, Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes, Blood, 118, e101, 10.1182/blood-2011-03-339705 Violi, 2014, Platelet NOX, a novel target for anti-thrombotic treatment, Thromb Haemost, 111, 817, 10.1160/TH13-10-0818 Cahilly, 2000, A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis, Circ Res, 86, 391, 10.1161/01.RES.86.4.391 Andreassi, 2012, Individual and summed effects of high-risk genetic polymorphisms on recurrent cardiovascular events following ischemic heart disease, Atherosclerosis, 223, 409, 10.1016/j.atherosclerosis.2012.05.029 Arca, 2008, C242T polymorphism of NADPH oxidase p22phox and recurrence of cardiovascular events in coronary artery disease, Arterioscler Thromb Vasc Biol, 28, 752, 10.1161/ATVBAHA.107.154823 Kakko, 2003, The signal sequence polymorphism of the MnSOD gene is associated with the degree of carotid atherosclerosis, Atherosclerosis, 168, 147, 10.1016/S0021-9150(03)00091-1 Fujimoto, 2008, Manganese superoxide dismutase polymorphism affects the oxidized low-density lipoprotein-induced apoptosis of macrophages and coronary artery disease, Eur Heart J, 29, 1267, 10.1093/eurheartj/ehm500 Marklund, 1997, Two variants of extracellular-superoxide dismutase: relationship to cardiovascular risk factors in an unselected middle-aged population, J Intern Med, 242, 5, 10.1046/j.1365-2796.1997.00160.x Juul, 2004, Genetically reduced antioxidative protection and increased ischemic heart disease risk: the Copenhagen City Heart Study, Circulation, 109, 59, 10.1161/01.CIR.0000105720.28086.6C Hamanishi, 2004, Functional variants in the glutathione peroxidase-1 (GPx-1) gene are associated with increased intima-media thickness of carotid arteries and risk of macrovascular diseases in japanese type 2 diabetic patients, Diabetes, 53, 2455, 10.2337/diabetes.53.9.2455 Heslop, 2012, Combined polymorphisms in oxidative stress genes predict coronary artery disease and oxidative stress in coronary angiography patients, Ann Hum Genet, 76, 435, 10.1111/j.1469-1809.2012.00731.x Halliwell, 2013, The antioxidant paradox: less paradoxical now?, Br J Clin Pharmacol, 75, 637, 10.1111/j.1365-2125.2012.04272.x Bjelakovic, 2007, Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis, J Am Med Assoc, 297, 842, 10.1001/jama.297.8.842 Touyz, 2004, Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?, Hypertension, 44, 248, 10.1161/01.HYP.0000138070.47616.9d Bast, 2013, Ten misconceptions about antioxidants, Trends Pharmacol Sci, 34, 430, 10.1016/j.tips.2013.05.010 Milman, 2008, Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial, Arterioscler Thromb Vasc Biol, 28, 341, 10.1161/ATVBAHA.107.153965 Blum, 2010, The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes, Atherosclerosis, 211, 25, 10.1016/j.atherosclerosis.2010.02.018 Chandel, 2014, The promise and perils of antioxidants for cancer patients, N Engl J Med, 371, 177, 10.1056/NEJMcibr1405701